Merck's Keytruda wins FDA 'breakthrough' tag in colorectal cancer; Allergan nabs bowel drug rights in Europe;

> Merck & Co. ($MRK) won the FDA's breakthrough designation for its immuno-oncology therapy Keytruda in colorectal cancer; the drug is already approved to treat melanoma and lung cancer. Release

> Allergan ($AGN) bought the rights to Constella (linaclotide) in 40-plus countries, including major European markets, from Spain's Almirall; the drug is sold as Linzess in the U.S. Report

> New blockbuster drugs will drive big growth in the multiple myeloma market, GlobalData says, to $22.4 billion in sales by 2023, up from $8.9 billion in 2014. Report

> GlaxoSmithKline ($GSK), Roche ($RHHBY) and Sanofi ($SNY) all have major investor presentations this week, highlighting their R&D pipelines, and, in Sanofi's case, a new strategy from its new CEO, Olivier Brandicourt. Report

> Eisai said it's presenting data from an Asian Fycompa study in patients with difficult-to-treat partial-onset seizures, in which the drug topped placebo at cutting the frequency of seizures. Release

And Finally... The Novartis Foundation and its partners launched a hypertension screening effort in Ghana as part of a two-year test of an "innovative healthcare model" designed to control high blood pressure. Release

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.